Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Graft Versus Host Disease

Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors

Summary:

The aim of this study was to identify the risk factors for acute graft-versus-host disease (aGVHD) in children transplanted from a matched-sibling donor (MSD) or an unrelated donor (UD). In all, 87 children consecutively underwent allogeneic bone marrow transplantation (BMT) from MSD (n=36), and UD (n=51). GVHD prophylaxis included CsA alone (n=33) or with MTX (n=51). ATG was added in UD-BMT and thalassemic recipients. CsA whole-blood concentrations were measured by EMIT and the dosing regimen was monitored by Bayesian pharmacokinetic modelling. Trough blood concentration (TBC) during the first 2 weeks post transplantation was lower in children who developed grade II–IV aGVHD than those developing no GVHD or only grade I (57±9 vs 94±8 ng/ml, P=0.007), whereas peak blood concentration and area under concentration curve vs time were similar in both groups. TBC <85 ng/ml and ‘use of MTX’ were associated with aGVHD in MSD-SCT (P=0.003 and 0.007, respectively) as well as in UD-SCT (P=0.006 and 0.003). Donor age 8 years was significant only in MSD-BMT. Our results have shown the significant decisive role of pharmacological factors such as CSA TBC or use of MTX in the occurrence of GVHD in MSD as well as in UD paediatric BMT.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Locatelli F, Uderzo C, Dini G et al. Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A. Bone Marrow Transplant 1993; 12: 627–633.

    CAS  PubMed  Google Scholar 

  2. Locatelli F, Zecca M, Rondelli R et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukaemia given HLA-identical sibling bone marrow transplantation: results of a randomised trial. Blood 2000; 95: 1572–1579.

    CAS  PubMed  Google Scholar 

  3. Casper J, Camitta B, Truitt R et al. Unrelated bone marrow donor transplants for children with leukaemia or myelodysplasia. Blood 1995; 85: 2354–2363.

    CAS  PubMed  Google Scholar 

  4. Balduzzi A, Gooley T, Anasetti C et al. Unrelated donor marrow transplantation in children. Blood 1995; 86: 3247–3256.

    CAS  PubMed  Google Scholar 

  5. Oakhill A, Pamphilon DH, Potter MN et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996; 94: 574–578.

    Article  CAS  PubMed  Google Scholar 

  6. Davies SM, Wagner JE, Shu XO et al. Unrelated donor bone marrow transplantation for children with acute leukaemia. J Clin Oncol 1997; 15: 557–565.

    Article  CAS  PubMed  Google Scholar 

  7. Kondo M, Kojima S, Horibe K et al. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children. Bone Marrow Transplant 2001; 27: 727–730.

    Article  CAS  PubMed  Google Scholar 

  8. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of bone marrow grafts. N Engl J Med 1979; 300: 1068–1073.

    Article  CAS  PubMed  Google Scholar 

  9. Sullivan KM, Weiden PL, Storb R et al. Influence of acute and chronic graft-versus-host-disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukaemia. Blood 1989; 73: 1720–1728.

    CAS  PubMed  Google Scholar 

  10. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukaemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.

    CAS  PubMed  Google Scholar 

  11. Gratwohl A, Hermans J, Apperley J et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukaemia. Working party chronic leukaemia of the european group for blood and marrow transplantation. Blood 1995; 86: 813–818.

    CAS  PubMed  Google Scholar 

  12. Ringden O, Labopin M, Gluckman E et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Bone Marrow Transplant 1996; 18: 921–992.

    CAS  PubMed  Google Scholar 

  13. Ringden O, Hermans J, Labopin M et al. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Leukemia Lymphoma 1996; 24: 71–79.

    Article  CAS  PubMed  Google Scholar 

  14. Bortin MM, Rimm AA . Severe combined immunodeficiency disease. Characterization of the disease and results of transplantation. JAMA 1977; 238: 591–600.

    Article  CAS  PubMed  Google Scholar 

  15. Bortin MM, Rimm AA . Allogeneic bone marrow transplantation for 144 patients with severe aplastic anemia. JAMA 1981; 245: 1132–1139.

    Article  CAS  PubMed  Google Scholar 

  16. Zwaan FE, Hermans J . Bone marrow transplantation for leukemia: European results in 264 cases. Exp Hematol 1982; 10: 47–54.

    Google Scholar 

  17. Ramsay NKC, Kersey JH, Robison LL et al. A randomized study of the prevention of acute graft-versus -host disease. New Engl J Med 1982; 306: 392–397.

    Article  CAS  PubMed  Google Scholar 

  18. Bross DS, Tutschka PJ, Farmer ER et al. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow. Blood 1984; 63: 1265–1270.

    CAS  PubMed  Google Scholar 

  19. Bortin MM . Risk factors for acute graft-versus-host disease. Exp Hematol 1985; 13: 406–415.

    Google Scholar 

  20. Ringden O, Nilsson B . Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation 1985; 40: 39–44.

    Article  CAS  PubMed  Google Scholar 

  21. Atkinson K, Farrel C, Chapman G et al. Female marrow donors increase the risk of acute graft-versus-host disease: effect of donor age and parity and analysis of cell subpopulation in the donor marrow inoculum. Br J Haematol 1986; 63: 231–239.

    Article  CAS  PubMed  Google Scholar 

  22. Gale RP, Bortin MM, van Bekkum DW et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397–406.

    Article  CAS  PubMed  Google Scholar 

  23. Gratama JW, Stijnen T, Weiland HT et al. Herpes-virus immunity and acute graft-versus-host disease. Lancet 1987; i: 471–474.

    Article  Google Scholar 

  24. Boström L, Ringdén O, Sundberg B et al. Pretransplant herpes virus serology and acute GVHD. Transplantation 1988; 46: 548–552.

    Article  PubMed  Google Scholar 

  25. Boström L, Ringdén O, Gratama JW et al . A role of herpes virus serology for the development of acute graft-versus-host disease. Bone Marrow Transplant 1990; 5: 321–326.

    PubMed  Google Scholar 

  26. Nash RA, Pepe MS, Storb R et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838–1845.

    CAS  PubMed  Google Scholar 

  27. Hägglund H, Bostrom L, Remberger M et al. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplantation. Bone Marrow Transplant 1995; 16: 747–753.

    PubMed  Google Scholar 

  28. Storb R, Deeg HJ, Farewall V et al. Marrow transplantation for severe aplastic anaemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68: 119–124.

    CAS  PubMed  Google Scholar 

  29. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukaemia. N Engl J Med 1986; 314: 729–735.

    Article  CAS  PubMed  Google Scholar 

  30. Yee GC, Self SG, Mc Guire TR et al. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med 1988; 319: 65–70.

    Article  CAS  PubMed  Google Scholar 

  31. Przepiorka D, Shapiro S, Schwingammer TL et al. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease. Bone Marrow Transplant 1991; 7: 461–465.

    CAS  PubMed  Google Scholar 

  32. Ghalie R, Fitzsimmons WE, Weinstein A et al. Cyclosporine monitoring improves graft-versus-host disease prophylaxis after bone marrow transplantation. Ann Pharmacother 1994; 28: 379–383.

    Article  CAS  PubMed  Google Scholar 

  33. Eisner MD, August CS . Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant 1995; 15: 663–668.

    CAS  PubMed  Google Scholar 

  34. Souillet G, Rey S, Bertrand Y et al. Outcome of unrelated bone marrow donor searches in 174 children resulting in 45 patients transplanted in the HLA-matched and-mismatched situation. Bone Marrow Transplant 2000; 26: 31–43.

    Article  CAS  PubMed  Google Scholar 

  35. Laboratory of Applied Pharmacokinetics. USC* Pack P.C. Collection Clinical Research Programs. Los Angeles: University of Southern California, School of Medicine, 1995, version 10.7.

  36. Jelliffe RW, Schumitzky A, Van Guilder M et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 1993; 15: 380–393.

    Article  CAS  PubMed  Google Scholar 

  37. Jelliffe RW . Effect of assumptions concerning assay error patterns upon pharmacokinetic parameter values and model behavior. J Vet Pharmacol Ther 1994; 17: 105–109.

    Google Scholar 

  38. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  PubMed  Google Scholar 

  39. Beatty PG, Hansen JA, Longton GM et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443–447.

    Article  CAS  PubMed  Google Scholar 

  40. Hows J, Bradley BA, Gore S et al. Prospective evaluation of unrelated donor bone marrow transplantation. The international Marrow Unrelated Search and Transplant (IMUST) Study. Bone Marrow Transplant 1993; 12: 371–380.

    CAS  PubMed  Google Scholar 

  41. Grevel J, Welsh MS, Kahan BD . Cyclosporine monitoring in renal transplantation : area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit 1989; 11: 246–248.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to N Bleyzac.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Martin, P., Bleyzac, N., Souillet, G. et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 32, 881–887 (2003). https://doi.org/10.1038/sj.bmt.1704239

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704239

Keywords

  • acute GVHD
  • risk factor
  • cyclosporine
  • paediatrics

This article is cited by

Search

Quick links